BENJAMIN ROY: Open Payments
NPI 1013021492 · COLUMBUS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,049 in 109 payments from 12 companies in 2025. Trend: 2023 $890 · 2024 $1,362 · 2025 $2,049
Food & beverage: $2,049
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 13 | $291 |
| E.R. Squibb & Sons, L.L.C. | 14 | $281 |
| Vanda Pharmaceuticals Inc. | 15 | $242 |
| Teva Pharmaceuticals USA, Inc. | 14 | $227 |
| Otsuka America Pharmaceutical, Inc. | 11 | $226 |
| Supernus Pharmaceuticals, Inc. | 12 | $176 |
| Alkermes, Inc. | 9 | $175 |
| Axsome Therapeutics, Inc. | 7 | $174 |
| ABBVIE INC. | 6 | $96 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $81 |
Products named: INGREZZA, COBENFY, FANAPT, AUSTEDO XR, Qelbree, ARISTADA, Auvelity, ABILIFY MAINTENA.
Industry payments across GA — which companies pay providers there.
